We are currently investing out of two vehicles – NLV-IV for venture investments and NLV Biopharma Opportunities II for private and public growth-stage biopharmaceuticals investments – and actively managing our fully committed portfolios – NLV-I, NLV-II, NLV-III and NLV Biopharma Opportunities I – to advance the possibilities of healthcare by building the most innovative businesses that develop clinically important and commercially attractive healthcare solutions.
NLVP was formed in 2005, when the healthcare team spun out of the Sprout Group. The NLVP team has been built over the last two decades and managed healthcare technology portfolios in four Sprout funds and four New Leaf funds. We partner with companies across all phases, from startup to public offerings, as we look to invest in visionary teams, businesses at the forefront of biology and innovation, and disruptive healthcare technologies across the entire healthcare system. And we share our broad perspectives, decades of experience and deep domain expertise to help our portfolio navigate the complexity of the healthcare industry.